Brief Title
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)
Official Title
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)
Brief Summary
Treatment of tauopathies such as Progressive Supranuclear Palsy (PSP) and Cortico Basal Degeneration (CBD) remains a major challenge. These rare severe neurodegenerative extrapyramidal movement disorders share phenotypic overlap and are usually painful. Parkinson disease (PD) is a common extrapyramidal movement disorder and continuous subcutaneous apomorphine infusion (CSAI) is commonly used in advanced PD patients to alleviate motor and non-motor fluctuations. Effects of subcutaneous apomorphine were investigated especially on pain and, on quality of life in 7 patients with PSD or CBD.This is an observational "real life" surveillance-based study.The Verbal Rating Scale for Pain (VRS) was used to assess changes in pain level and the clinical global impression-improvement scale (CGI-I) was used to assess changes in patient's illness before and during six months of treatment. Detailed report of the symptoms and side effects has been recorded by home nurses throughout the study period.
Study Type
Observational
Primary Outcome
Effects of subcutaneous apomorphine on pain
Condition
Progressive Supranuclear Palsy
Intervention
Apomorphine
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
7
Start Date
December 1, 2018
Completion Date
July 1, 2020
Primary Completion Date
June 1, 2020
Eligibility Criteria
Inclusion Criteria: - PSP or CBD patients for whom a treatment with subcutaneaous apomorphine is indicated Exclusion Criteria: - Pregnant or breastfeeding women - Patient under a legal protection procedure - Patient denying to participated to the study - Lack of affiliation to a social security system
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT04786158
Organization ID
CE_20200204_5_CHH
Responsible Party
Sponsor
Study Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Study Sponsor
, ,
Verification Date
March 2021